Oncolix Inc. (fka ONCX)

[laraz5]

What proof does anyone have that Oncolix is in some form of phase 1 cohort? besides a PR from Oncolix?

I've been looking into companies who are actually in the same phase cohort as Oncolix and on the Gov website, Oncolix is not listing itself as being in Phase 1 cohort, nor do they provide descriptions of currently operations? The description is years old? a 90 day trial with no results in years does not make sense?

Every company I have looked into so far provides Information all about the different phases of the cohorts?

example of a company with detailed description

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 18 participants
Intervention Model: Sequential Assignment
Intervention Model Description: Study will enroll 3 patients to the cohort 1 dose level. If 0 of 3 patients experience a DLT, the study will proceed to cohort 2. If 1 patient experiences a DLT, 3 additional patients will be enrolled into cohort 1. If 1 of 6 patients experience a DLT, the study will proceed and 3 patients will be enrolled to the cohort 2 dose level. If 0 patients experience a DLT in cohort 2, the study will proceed to cohort 3. If 1 patient experiences a DLT at cohort 2, 3 additional patients will be enrolled into cohort 2. If the study proceeds to cohort 3, 3 patients will be enrolled at this dose level. If 0 patients experience a DLT, the study will enroll an additional 3 patients at the cohort 3 dose level to better define the safety profile. If 1 of 3 patients experiences a DLT at cohort 3, 3 additional patients will still be enrolled into cohort 3. If 1 of 6 patients experience a DLT, the study will complete.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
Actual Study Start Date : January 19, 2018
Estimated Primary Completion Date : August 1, 2019
Estimated Study Completion Date : January 1, 2020



Now Oncolix Prolanta


Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 18 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Open-Label, Dose-Escalation and Pharmacokinetic Study of Subcutaneous Prolanta™ in Subjects With Recurrent or Persistent Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Study Start Date : February 2016
Estimated Primary Completion Date : February 2019
Estimated Study Completion Date : February 2019


This is bizarre and the lack of transparency is what has Investors bailing

IMO